Atorvastatin for the Treatment of Plaque‐Type Psoriasis

Faghihi, Toktam; Radfar, Mohammad Hadi; Mehrabian, Zohre; Ehsani, Amir H; Hemami, Mohsen Rezaei

doi:10.1592/phco.31.11.1045

Cited by 25 publications

(35 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Troglitazone normalized histological features in psoriasis models and the lesional phenotype in a small clinical trial [48]. The “HMG CoA reductase inhibitor” drug simvastatin was effective in a pilot study, although atorvastatin in the same class showed only a non-significant improvement in a different study [49], [50]. Salicylic acid has antifungal effects and it's used as adjuvant because of its keratolytic effect in the treatment of psoriasis [51].…”

Section: Resultsmentioning

confidence: 99%

Novel Factors in the Pathogenesis of Psoriasis and Potential Drug Candidates Are Found with Systems Biology Approach

Manczinger

Kemény

2013

PLoS ONE

View full text Add to dashboard Cite

Psoriasis is a multifactorial inflammatory skin disease characterized by increased proliferation of keratinocytes, activation of immune cells and susceptibility to metabolic syndrome. Systems biology approach makes it possible to reveal novel important factors in the pathogenesis of the disease. Protein-protein, protein-DNA, merged (containing both protein-protein and protein-DNA interactions) and chemical-protein interaction networks were constructed consisting of differentially expressed genes (DEG) between lesional and non-lesional skin samples of psoriatic patients and/or the encoded proteins. DEGs were determined by microarray meta-analysis using MetaOMICS package. We used STRING for protein-protein, CisRED for protein-DNA and STITCH for chemical-protein interaction network construction. General network-, cluster- and motif-analysis were carried out in each network. Many DEG-coded proteins (CCNA2, FYN, PIK3R1, CTGF, F3) and transcription factors (AR, TFDP1, MEF2A, MECOM) were identified as central nodes, suggesting their potential role in psoriasis pathogenesis. CCNA2, TFDP1 and MECOM might play role in the hyperproliferation of keratinocytes, whereas FYN may be involved in the disturbed immunity in psoriasis. AR can be an important link between inflammation and insulin resistance, while MEF2A has role in insulin signaling. A controller sub-network was constructed from interlinked positive feedback loops that with the capability to maintain psoriatic lesional phenotype. Analysis of chemical-protein interaction networks detected 34 drugs with previously confirmed disease-modifying effects, 23 drugs with some experimental evidences, and 21 drugs with case reports suggesting their positive or negative effects. In addition, 99 unpublished drug candidates were also found, that might serve future treatments for psoriasis.

show abstract

Section: Resultsmentioning

confidence: 99%

Novel Factors in the Pathogenesis of Psoriasis and Potential Drug Candidates Are Found with Systems Biology Approach

Manczinger

Kemény

2013

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Such actions of statins include inhibiting the release of inflammatory cytokines such as TNF‐α, IL‐1 and IL‐6, which are implicated in psoriasis 48 . However, clinical evidence for the effectiveness of statins on psoriasis is inconclusive 49–53 . Of note, multiple studies have also found that treatment with TNF inhibitors has no effect on patients’ lipid profiles, with additional studies reporting small increases in plasma lipid levels from TNF inhibitors 54–58 …”

Section: Discussionmentioning

confidence: 99%

“…48 However, clinical evidence for the effectiveness of statins on psoriasis is inconclusive. [49][50][51][52][53] Of note, multiple studies have also found that treatment with TNF inhibitors has no effect on patients' lipid profiles, with additional studies reporting small increases in plasma lipid levels from TNF inhibitors. [54][55][56][57][58] Medications may modulate the relationship between psoriasis and dyslipidaemia.…”

Section: Discussionmentioning

confidence: 99%

The association between psoriasis and dyslipidaemia: a systematic review

Harskamp

Armstrong

et al. 2013

British Journal of Dermatology

146

View full text Add to dashboard Cite

Psoriasis may be associated with dyslipidaemia, a known risk factor for cardiovascular disease. This systematic review aims to synthesize evidence for the association between psoriasis and dyslipidaemia. Through a systematic search using MEDLINE, Embase and the Cochrane Central Register, from 1 January 1980 to 1 January 2012, we identified 25 observational studies that met the inclusion criteria. These 25 studies included over 2·4 million participants, among whom 265,512 were patients with psoriasis. Twenty studies (80%) reported that psoriasis was significantly associated with dyslipidaemia, with odds ratios (ORs) for dyslipidaemia ranging from 1·04 to 5·55 in 238,385 patients with psoriasis, from a population of 2,340,605 participants. Specifically, four studies defining dyslipidaemia as triglyceride levels ≥ 150 mg dL reported significantly increased ORs of 1·20-4·98 for hypertriglyceridaemia in psoriasis. Three studies found that patients with psoriasis presented with significantly increased ORs (1·36-1·77) for high-density lipoprotein cholesterol levels < 40 mg dL , and two studies found hyperlipoproteinaemia to be significantly elevated in patients with psoriasis (ORs 1·55 and 2·09). One cohort study found a significantly higher incidence of hyperlipidaemia among patients with psoriasis (hazard ratio 1·17; 95% confidence interval 1·11-1·23). Among studies that assessed the severity of psoriasis, in 2662 patients with mild psoriasis and 810 patients with severe psoriasis, higher odds of dyslipidaemia were seen in patients with severe psoriasis. Five of the 25 studies (20%) in our review did not show any significant relationship between psoriasis and dyslipidaemia. This systematic review found that psoriasis was significantly associated with greater odds and incidence of dyslipidaemia. Greater psoriasis severity appeared to be associated with higher prevalence of dyslipidaemia.

show abstract

“…2 Researchers have also investigated the possibility of using statins in inflammatory conditions as diverse as psoriasis 3 and multiple sclerosis, 4 although the evidence remains limited. Hypotheses about the mechanisms of these anti-inflammatory effects include the inhibition of proinflammatory cytokines and reduced T cell activation.…”

mentioning

confidence: 99%

Statin Use and Osteoarthritis

Rashid

2013

J GEN INTERN MED

View full text Add to dashboard Cite

Atorvastatin for the Treatment of Plaque‐Type Psoriasis

Cited by 25 publications

References 32 publications

Novel Factors in the Pathogenesis of Psoriasis and Potential Drug Candidates Are Found with Systems Biology Approach

Novel Factors in the Pathogenesis of Psoriasis and Potential Drug Candidates Are Found with Systems Biology Approach

The association between psoriasis and dyslipidaemia: a systematic review

Statin Use and Osteoarthritis

Contact Info

Product

Resources

About